Biotech Values

[staccani]

CNAT: ph2b - POLT SRV HCV trial
If you look at clinical trials website, the estimated primary completion date is still February 2018. The trial must have finished and they are collecting/have collected the data for analysis. The estimated completion date is March 2018 (and this is based on 2 years treatment)

Moreover from the clinical trial change history you will see that by Feb 5th 2016 the trial was fully enrolled (since changing the status from active & recruiting to active & not recruiting), so all patients had been on trial for 24 months as of Feb 5th 2018
I would not be surprised if the results are published in March (a little bit earlier than the company q2 indication, maybe they had just forecasted some extra time for the analysis to avoid hurry), but, if not in March, I am quite confident results will be out by April 2018 at latest.
This would also explain recent Spada shares addition and recent Oppenheimer and Roth strong buy recommendations (1 year TP of $16 and $20 respectively).
Unfortunately (or fortunately for us) CNAT has a long history of substantial share price movements on significant volumes in anticipation of (good) results, so yesterday's move might just be the beginning.
This first trial is VERY important, as it is the first trial with 2 years Emricasan dosing, for both efficacy and safety , it covers both fibrosis and cirrhosis and it has histology measurement for the first time so it will provide us a very strong indication of what to expect from the other 3 ph2b's trials


https://clinicaltrials.gov/ct2/show/record/NCT02138253
https://clinicaltrials.gov/archive/NCT02138253/2016_02_05/changes